These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 32494152)

  • 1. Erratum: Antitumor Activity of Larotrectinib in Tumors Harboring
    Onco Targets Ther; 2020; 13():3975. PubMed ID: 32494152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
    Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
    Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Larotrectinib OK'd for Cancers with
    Cancer Discov; 2019 Jan; 9(1):8-9. PubMed ID: 30510115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TRK Inhibition: A New Tumor-Agnostic Treatment Strategy.
    Kummar S; Lassen UN
    Target Oncol; 2018 Oct; 13(5):545-556. PubMed ID: 30276762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an
    Farago AF; Taylor MS; Doebele RC; Zhu VW; Kummar S; Spira AI; Boyle TA; Haura EB; Arcila ME; Benayed R; Aisner DL; Horick NK; Lennerz JK; Le LP; Iafrate AJ; Ou SI; Shaw AT; Mino-Kenudson M; Drilon A
    JCO Precis Oncol; 2018; 2018():. PubMed ID: 30215037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [NTRK Fusions: A new way of treatment for gastro-intestinal tumor?].
    Ouali K; Pellat A; Cohen R; Svrcek M; Penault-Llorca F; André T
    Bull Cancer; 2020 Apr; 107(4):447-457. PubMed ID: 32067719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A Case of Pediatric Soft Tissue Sarcoma with LMNA-NTRK1 Gene Fusion Treated with Larotrectinib under Single Patient Expanded Access System].
    Kato S; Fujimura J; Nozaki Y; Yamaguchi S; Takagi T; Hayashi T; Saito T; Henry D; Ku N; Suehara Y
    Gan To Kagaku Ryoho; 2019 Oct; 46(10):1595-1597. PubMed ID: 31631147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of NTRK expression in gastric and esophageal adenocarcinoma (AGE) with pan-TRK immunohistochemistry.
    Arnold A; Daum S; von Winterfeld M; Berg E; Hummel M; Horst D; Rau B; Stein U; Treese C
    Pathol Res Pract; 2019 Nov; 215(11):152662. PubMed ID: 31575452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy.
    Hsiao SJ; Zehir A; Sireci AN; Aisner DL
    J Mol Diagn; 2019 Jul; 21(4):553-571. PubMed ID: 31075511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Larotrectinib: First Global Approval.
    Scott LJ
    Drugs; 2019 Feb; 79(2):201-206. PubMed ID: 30635837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Larotrectinib for the treatment of TRK fusion solid tumors.
    Laetsch TW; Hawkins DS
    Expert Rev Anticancer Ther; 2019 Jan; 19(1):1-10. PubMed ID: 30350734
    [No Abstract]   [Full Text] [Related]  

  • 12. Erratum: Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection [Corrigendum].
    Onco Targets Ther; 2021; 14():5167-5168. PubMed ID: 34729014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erratum: Traditional Chinese Medicine
    Onco Targets Ther; 2022; 15():77-79. PubMed ID: 35087275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer.
    Federman N; McDermott R
    Expert Rev Clin Pharmacol; 2019 Oct; 12(10):931-939. PubMed ID: 31469968
    [No Abstract]   [Full Text] [Related]  

  • 15. Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors.
    Konicek BW; Capen AR; Credille KM; Ebert PJ; Falcon BL; Heady GL; Patel BKR; Peek VL; Stephens JR; Stewart JA; Stout SL; Timm DE; Um SL; Willard MD; Wulur IH; Zeng Y; Wang Y; Walgren RA; Betty Yan SC
    Oncotarget; 2018 Mar; 9(17):13796-13806. PubMed ID: 29568395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinicopathological characteristics of NTRK-rearranged mesenchymal tumors in childhood].
    Yin MZ; Ma J; He Q; Shen P; Chen JF; Jin XT; Zhang ZD; Kuick CH; Chen HY; Ng EHQ; Aw SJ; Chang KTE
    Zhonghua Bing Li Xue Za Zhi; 2020 Jul; 49(7):675-680. PubMed ID: 32610377
    [No Abstract]   [Full Text] [Related]  

  • 17. Erratum: Clinical Applications of Aneuploidies in Evolution of NSCLC Patients: Current Status and Application Prospect [Corrigendum].
    Onco Targets Ther; 2023; 16():141-142. PubMed ID: 36883048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NTRK-Fusions - A new kid on the block.
    Märkl B; Hirschbühl K; Dhillon C
    Pathol Res Pract; 2019 Oct; 215(10):152572. PubMed ID: 31400924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying patients with NTRK fusion cancer.
    Solomon JP; Benayed R; Hechtman JF; Ladanyi M
    Ann Oncol; 2019 Nov; 30(Suppl_8):viii16-viii22. PubMed ID: 31738428
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.